Merck ends nemtabrutinib development after the BELLWAVE program
FROM THE WIRE · FINANCE.YAHOO.COM
Merck MRK has made considerable progress in advancing the pipeline, particularly in areas like oncology, vaccines and infectious diseases, where it is developing several candidates with the potential to diversify the portfolio and expand the revenue base. MRK's phase III…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishDiscontinuing a hematology program is a negative step, though limited in scope for the group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Merck announced the discontinuation of the BELLWAVE clinical program on nemtabrutinib (MK-1026).
- 02Nemtabrutinib is an investigational oral non-covalent Bruton's tyrosine kinase inhibitor.
- 03The drug was being developed for chronic lymphocytic leukemia and other lymphomas.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets